Pneumagen Raises £3.8 Million To Advance The Phase Ii Clinical Development Of Neumifil, A Pan-Antiviral, Intranasal Drug For The Prophylaxis And Treatment Of Viral Respiratory Tract Infections (Rtis)

Company

About

Pneumagen is a clinical- stage biotech company developing Neumifil, its lead product, as an intranasal drug for the prophylaxis and treatment of a broad range of viral respiratory tract infections (RTIs). Neumifil is a novel, engineered multivalent Carbohydrate Binding Molecule (mCBM), which is being developed for the universal treatment of Influenza Virus (IFV), Respiratory Syncytial Virus (RSV), and coronavirus infections including COVID-19. Neumifil acts by directly binding and preventing the entry of the viral pathogens into the lungs with reduced susceptibility to direct viral resistance. Neumifil was generated using Pneumagen's proprietary GlycoTargeTM technology that acts by stopping viruses at the site of infection, reducing their ability both to enter cells and to migrate to the lungs. In addition to Neumifil, Pneumagen is harnessing its GlycoTargeTMplatform to enable the development of a pipeline of intranasal therapies targeting other infectious lung diseases. Pneumagen was established in 2016 as a spin-out from the University of St Andrews in Scotland giving Pneumagen access to world-class scientific expertise and capabilities in viral RTI's specifically related to glycobiology.